Axiron Q3 sales were US $40.6m.
Axiron Q4 sales were US $53.9m.
Thus, Axiron Q4 sales were up 32.8% on previous quarter.
In the AFR article, the Wilson HTM analyst estimated (in mid-January) Axiron Q4 sales of US $41.3m.
Actual Q4 sales reported by ACR/Lily were US $53.9m.
Thus, analysts expectations were beaten by 30.5%.
SP closed at $2.35 on 30th January - on the eve of the Axiron sales update.
SP closed at $2.08 at time of trading halt today - 2.5 trading days after sales update and sudden SP plunge.
Overall, SP has dropped 11.49% in 2.5 days after positive sales figures were released.
While I appreciate that there is some newly developed concern that TRT may lead to increased risk of heart attack and stroke, and that sales of Axiron may suffer in the future, at the moment, in the face of such positive sales data, I can't help but feel that people are panicking and jumping the gun.
Total Axiron sales in US market for 2013 were US $178.7m.
Having exceeded sales of US $100m in a calendar year, Acrux will receive bonus US $25m milestone payment from Lily in March.
Based on ACR's most recent sales update announcement, most or all of this payment will be distributed to shareholders.
WTF people???!!!
Add to My Watchlist
What is My Watchlist?
